Conor Kilroy Biography and Net Worth

Insider of Aura Biosciences

Conor Kilroy is Chief Legal Officer and Secretary at Aura. Before joining Aura, Mr. Kilroy was most recently general counsel and secretary at Neurogastrx, Inc. and previously served as general counsel and secretary at Ironwood Pharmaceuticals, Inc., among other roles. Earlier in his carrier, Mr. Kilroy held roles at Boston Scientific Corporation and in the business law department of Goodwin Procter LLP. Mr. Kilroy holds a J.D. from Boston College Law School and a B.A. from Brandeis University.

What is Conor Kilroy's net worth?: The estimated net worth of Conor Kilroy is at least $1.16 million as of April 16th, 2025. Mr. Kilroy owns 179,313 shares of Aura Biosciences stock worth more than $1,156,569 as of December 4th. This net worth evaluation does not reflect any other assets that Mr. Kilroy may own. Learn More about Conor Kilroy's net worth.
How do I contact Conor Kilroy?: The corporate mailing address for Mr. Kilroy and other Aura Biosciences executives is , , . Aura Biosciences can also be reached via phone at 617-500-8864 and via email at [email protected]. Learn More on Conor Kilroy's contact information.
Has Conor Kilroy been buying or selling shares of Aura Biosciences?: Conor Kilroy has not been actively trading shares of Aura Biosciences in the last ninety days. Most recently, Conor Kilroy sold 7,162 shares of the business's stock in a transaction on Wednesday, April 16th. The shares were sold at an average price of $5.49, for a transaction totalling $39,319.38. Following the completion of the sale, the insider now directly owns 179,313 shares of the company's stock, valued at $984,428.37. Learn More on Conor Kilroy's trading history.
Who are Aura Biosciences' active insiders?: Aura Biosciences' insider roster includes Elisabet de los Pinos (Insider), Amy Elazzouzi (SVP), Anthony Gibney (Insider), Janet Hopkins (Chief Medical Officer and President of Research & Development), David Johnson (Director), Conor Kilroy (Insider), and Mark Plavsic (CTO). Learn More on Aura Biosciences' active insiders.
Are insiders buying or selling shares of Aura Biosciences?: In the last twelve months, Aura Biosciences insiders bought shares 2 times. They purchased a total of 70,000 shares worth more than $343,000.00. In the last twelve months, insiders at the sold shares 13 times. They sold a total of 79,568 shares worth more than $514,201.11. The most recent insider tranaction occured on November, 17th when insider Janet Jill Hopkins sold 17,109 shares worth more than $92,730.78. Insiders at Aura Biosciences own 6.3% of the company. Learn More about insider trades at Aura Biosciences.
Information on this page was last updated on 11/17/2025.

Conor Kilroy Insider Trading History at Aura Biosciences

Transaction Date	Buy/Sell	Number of Shares	Average Share Price	Total Transaction	Shares Held After Transaction	Details
4/16/2025	Sell	7,162	$5.49	$39,319.38	179,313

Conor Kilroy Buying and Selling Activity at Aura Biosciences

Aura Biosciences Company Overview

Aura Biosciences, Inc., a clinical-stage biotechnology company, develops precision immunotherapies to treat a range of solid tumors. The company's proprietary platform enables the targeting of a range of solid tumors using virus-like particles conjugated with drugs or loaded with nucleic acids to create virus-like drug conjugates. Its lead candidate is bel-sar, which is in late-stage clinical development for the treatment of patients with primary choroidal melanoma and other ocular oncology indications, as well as in early-stage clinical development in bladder cancer. The company also focuses on assessing the safety and efficacy of bel-sar in treating a range of other solid tumors, including bladder cancer as an alternative to bacillus calmetteguérin therapy. Aura Biosciences, Inc. was incorporated in 2009 and is headquartered in Boston, Massachusetts.

Today's Range

Now: $6.45

$6.21

$6.53

50 Day Range

MA: $5.92

$5.35

$6.61

2 Week Range

Now: $6.45

$4.34

$9.14

Volume

117,755 shs

Average Volume

200,153 shs

Market Capitalization

$409.58 million

P/E Ratio

N/A

Dividend Yield

N/A

Beta

0.44